Compare FOSL & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FOSL | RCKT |
|---|---|---|
| Founded | 1984 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 418.7M | 394.2M |
| IPO Year | 1994 | 2014 |
| Metric | FOSL | RCKT |
|---|---|---|
| Price | $7.16 | $2.31 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 14 |
| Target Price | ★ $9.25 | $8.58 |
| AVG Volume (30 Days) | 733.7K | ★ 2.1M |
| Earning Date | 11-12-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 25.26 | ★ 26.37 |
| EPS | N/A | ★ 0.66 |
| Revenue | ★ $1,004,406,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.39 | $915.60 |
| P/E Ratio | ★ N/A | $3.76 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.70 | $2.42 |
| 52 Week High | $7.33 | $5.45 |
| Indicator | FOSL | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 69.18 | 26.79 |
| Support Level | $3.74 | N/A |
| Resistance Level | $7.33 | $4.02 |
| Average True Range (ATR) | 0.38 | 0.18 |
| MACD | 0.05 | -0.02 |
| Stochastic Oscillator | 88.98 | 2.61 |
Fossil Group Inc is a design, innovation, and distribution company in consumer fashion accessories, offering products such as watches, jewelry, handbags, small leather goods, belts, and sunglasses. It designs, develops, markets, and distributes products under its owned brands FOSSIL, SKAGEN, MICHELE, RELIC, and ZODIAC. It operates through Americas, Europe, and Asia segments, each including sales to wholesale and distributor customers, as well as Company-owned retail stores and e-commerce activities based on the location of the selling entity. The Americas segment contributes the majority of revenue and includes sales across Canada, Latin America, and the United States, while the Europe and Asia segments cover their respective regions. Each segment provides similar products and services.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.